Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis

Table 2 Hospitalizations during the 6-month follow up period

Variable	Medicaid population				Commercial population
	Lurasidone		Quetiapine		Lurasidone		Quetiapine
	n = 122		n = 215		n = 116		n = 220
Episodes (N)^a	125	–	226	–	118	–	223	–
All-cause hospitalizations
Episodes with ≥1 admission, (N, %)	19	15	52	23	12	10	44*	20
Length of stay (first admission), (Mean, SD)	5.4	4.3	6.7*	4.8	10.9	14.5	9.3	8.8
Cost, among episodes with an admission (Mean, SD)	15,448	13,741	22,012*	23,581	16,265	16,377	27,368*	46,415
Mental health-related hospitalizations
Episodes with ≥1 admission, (N, %)	18	14	48	21	10	9	42*	19
Length of stay (first admission), (Mean, SD)	5.6	4.4	6.8*	5.0	12.5	15.5	9.8*	8.8
Cost, among episodes with an admission (Mean, SD)	15,388	13,609	22,272*	24,385	16,512	17,903	27,398*	46,476
Schizophrenia-related hospitalizations
Episodes with ≥1 admission, (N, %)	16	13	36	16	8	7	26	12
Length of stay (first admission), (Mean, SD)	5.6	4.7	7.6*	5.0	14.4	17.0	13.8	21.7
Cost, among episodes with an admission (Mean, SD)	14,193	12,876	21,579*	24,034	17,863	19,745	18,514	17,249

^aMonotherapy treatment episodes were defined as patients having more than one lurasidone or quetiapine prescription without overlapping other antipsychotics during the post-index period. As some patients had multiple episodes, the N value in this row refers to the number of episodes in the sample that were evaluated
*(p < .05); Statistically significantly different from lurasidone cohort

ISSN: 1472-6963